Remove 2025 Remove Patients Remove Prescription
article thumbnail

Medicare Part D: Navigating Plans and Potential Gaps in 2025

Pharmaceutical Commerce

With a 26% decline in prescription drug plans from 2024 to 2025, navigating potential gaps and accessing care remains vital for low income patients.

article thumbnail

New Reimbursement Opportunities for Digital Mental Health Treatment in 2025: CMS’ Final Rule

Nixon Gwilt Law

CMS issued its 2025 Medicare Physician Fee Schedule (the “2025 MPFS” or “Final Rule”) on November 1, 2024. The Final 2025 MPFS contains some modifications and clarifications to several elements of the original proposal released in July 2024 (the “Proposed Rule”), which we discussed in this earlier post.

FDA 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

New Reimbursement Opportunities for Digital Mental Health Treatment in 2025: CMS’ Final Rule

Nixon Gwilt Law

CMS issued its 2025 Medicare Physician Fee Schedule (the “2025 MPFS” or “Final Rule”) on November 1, 2024. The Final 2025 MPFS contains some modifications and clarifications to several elements of the original proposal released in July 2024 (the “Proposed Rule”), which we discussed in this earlier post.

FDA 52
article thumbnail

Cosette acquires worldwide rights to Endoceutics’ Intraros prescription drug

Pharma Leaders

Cosette Pharmaceuticals has acquired the worldwide rights to prescription drug, Intraros, from Endorecherche’s subsidiary Endoceutics. It is expected to be launched in Asian market in 2025. Intrarosa is said to be the only prescription drug that provides estrogen as well as androgen to treat moderate-to-severe dyspareunia.

article thumbnail

Highlights from The Data Ecosystem in 2025

Prognos Health

This in-person event brought healthcare leaders together to discuss emerging opportunities and challenges around the use of health data to improve patient outcomes. More data should uncover more info about the patient. This includes clinical sensors and devices providing patient-generated data. Data key for health equity.

article thumbnail

Are new weight loss drugs an answer or problem?

World of DTC Marketing

Novo Nordisk more than doubled its sales targets for obesity drugs to $3.7bn by 2025. It has to persuade patients to sign up for some heinous side effects. When patients stop taking Wegovy, their appetite returns within weeks, and they pack on weight. Its share price has risen 26 percent in the past year.

article thumbnail

Innovating allergy drug delivery with a needle-free alternative

European Pharmaceutical Review

These factors may increase the likelihood that patients and caregivers carry it regularly. Thus, ARS Pharmaceuticals anticipates approval by Q1 2025 in the UK and launch by summer 2025. What is significant about approval of EURneffy as the first new delivery method in over three decades for adrenaline?